Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard

Nasdaq notified Actuate Therapeutics that its stock closed below $1.00 for 30 days, violating listing rules. The company has until April 26, 2027, to comply. It also faces a market value deficiency deadline of January 11, 2027. Trading is unaffected.

Original reporting
Published Oct 30, 2026, 8:13 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 30, 2026, 8:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Actuate Therapeutics Disclosed Failure to Satisfy a Continued Listing Rule or Standard — source image
Decision brief

The 30-second read

$ACTUBearishLow
01

Why it matters

The filing signals a compliance risk that could lead to delisting if not remedied by the April 26, 2027 deadline, likely prompting short‑term sell pressure.

02

Market read

A primary disclosure of a delisting notice for a micro‑cap biotech, creating immediate compliance risk and potential price downside.

03

What to watch

Potential for a reverse split or a strategic partnership that could restore compliance without a large cash infusion.

Relevance 6/10Novelty 6/10Timing: immediate

Background

Actuate Therapeutics (ACTU) received a Nasdaq Listing Rule 5450(a)(1) notice for trading below the $1 minimum bid price for 30 consecutive business days and a market‑value deficiency.

Company-level read

Ticker impact

$ACTUBearishHigh confidence
Context

Nasdaq notified Actuate Therapeutics that its share price fell below $1 for 30 days, triggering a delisting compliance notice.

Expected impact

likely downward pressure as investors price in potential delisting risk

Evidence & confidence

Compliance failures on low‑price listings historically lead to share sell‑offs until the company regains $1 price or raises capital.

Market effects

May raise scrutiny on other micro‑cap biotech stocks hovering near $1 listing thresholds.

Limited to U.S. Nasdaq micro‑cap segment; no broader regional effect.

Minimal global impact; primarily a company‑specific compliance issue.

Counterpoint

If Actuate can secure a capital raise quickly, the delisting risk may be short‑lived and present a buying opportunity at depressed prices.

Key entities

  • Actuate Therapeutics, Inc.

    Biotech firm listed on Nasdaq under ticker ACTU.

  • Nasdaq

    Exchange that issued the compliance notice.

Related articles

$ACTUMed

Actuate reports preclinical data on oral elraglusib in melanoma

Actuate Therapeutics (ACTU) reported preclinical data showing its oral drug candidate elraglusib achieved up to 77% tumor growth inhibition in a melanoma model. The company plans to initiate a Phase 1/2 clinical trial in Q1 2027, starting with refractory metastatic melanoma patients. Elraglusib has previously shown promise in a Phase 2 trial for metastatic pancreatic cancer.

$ACTUMedAI 8/10

Actuate Advances Oral Elraglusib Toward 2027 Trial Following Positive Melanoma Data

Actuate Therapeutics (ACTU) reported positive preclinical data for its oral elraglusib tablet, showing tumor growth inhibition and immune-modulating effects in a melanoma mouse model. The company plans to present the findings at the EORTC-NCI-AACR Symposium in November 2026 and initiate a Phase 1/2 clinical trial in Q1 2027. The U.S. Patent Office issued a Notice of Allowance for the oral formulation's patent.

$MARAMed

MARA prices $185M debt offering after $1.1B Bitcoin sale

MARA priced an $185M debt offering at 8.75% interest, maturing in 2032, to finance its $1.5B acquisition of Long Ridge Energy. The deal includes a 485MW power plant and land for potential data centers. MARA recently sold $1.1B in Bitcoin to repay debt. Long Ridge generated $144M in annualized adjusted EBITDA, but interest payments may consume nearly half.

$RIOLow

Rio Tinto commits US$250m to address damage from Bougainville's Panguna mine

Rio Tinto will contribute $250m to a fund addressing environmental and human rights impacts of the Panguna mine, per an agreement with Bougainville Copper Limited, the Autonomous Bougainville Government, and community leaders. The fund aims to support practical responses to identified impacts and social projects. Details will be developed in consultation with communities.